MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its participation in the 47th annual Association of Pediatric Hematology/Oncology Nurses (“APHON”) Conference and Exhibit, to be held in Cleveland, Ohio from Thursday, September 21 to Saturday, September 23, 2023. Covalon invites all attendees to booth 425 at the Huntington Convention Center, where they can explore our compassionate infection prevention solutions tailor made for pediatric patients.
“At Covalon, we deeply believe that healing shouldn’t hurt,” said Ron Hebert, Senior Vice President, Marketing, Covalon. “We understand that nurses, our frontline heroes, require the best tools to deliver the most compassionate care, which is one of the reasons 9 of the top 10 US pediatric cancer treatment hospitals now use Covalon’s technology. We’re proud to introduce our advanced vascular access solutions and dressings to attendees of the APHON Conference.”
The APHON Conference serves as a nexus for the brightest minds in pediatric hematology/oncology nursing. Attendees will have the opportunity to connect with global leaders, earn continuing education credits, and explore ground-breaking research and new technology.
Covalon’s patented infection prevention and wound care products include:
- VALGuard® - a transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal.
- SurgiClear® - the world's only dual-antimicrobial clear postoperative dressing that provides full surgical site visibility, allowing for visual site inspection and thus eliminating the need for early and multiple dressing removals.
- IV Clear® - the world’s only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It also utilizes soft silicone adhesive technology to minimize skin injuries and preserve skin barrier functions, and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation.
To book an appointment with a Covalon representative, please email Ron Hebert, SVP Marketing, Covalon Technologies Ltd., at firstname.lastname@example.org.
Dates: September 21 – 23, 2023
Location: Huntington Convention Center (300 Lakeside Ave. E, Cleveland, OH 44113, United States)
Register at: https://www.aphon.org/event/aphon-23-47th-annual-conference-exhibit-cleveland-ohio
For healthcare providers who are not able to attend the conference but are interested in learning more about Covalon’s solutions, visit www.covalon.com or follow Covalon on LinkedIn, Facebook, Instagram or Twitter.
Covalon Technologies Ltd. is a patient-driven medical device company, built on the relentless pursuit to help the most vulnerable patients have a better chance at healing. Through a strong portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, we offer innovative, gentler, and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon’s name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur”, or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management’s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the “Risks and Uncertainties” section of our management’s discussion and analysis of financial condition and results of operations for the year ended September 30, 2022, which is available on the Company’s profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.